Integrum (publ) announced that the European Union Intellectual Property Office, EUIPO, has approved Integrum's product registration application for the OPRA® Implant System. Until now, the OPRA® Implant system has been an unregistered mark without legal protection. As it is granted a registered trademark, Integrum now obtains unitary immaterial protection for the product in the entire territory of the EU.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54.8 SEK | +3.40% | +7.87% | +20.04% |
05-30 | Integrum AB Reports Earnings Results for the Fourth Quarter and Full Year Ended April 30, 2024 | CI |
05-29 | Integrum Receives Market Approval for Opra®? Implant System in Israel | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.04% | 95.85M | |
-13.90% | 20.77B | |
+5.10% | 19.18B | |
+12.84% | 10.53B | |
-20.92% | 1.97B | |
-3.83% | 1.63B | |
+9.55% | 1.34B | |
+3.95% | 542M | |
0.00% | 407M | |
+57.45% | 182M |
- Stock Market
- Equities
- INTEG B Stock
- News Integrum AB
- Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu